Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 SEK | -.--% | +4.99% | -9.98% |
Feb. 06 | Transcript : Boule Diagnostics AB, 2023 Earnings Call, Feb 06, 2024 | |
Feb. 06 | Transcript : Boule Diagnostics AB, 2023 Earnings Call, Feb 06, 2024 |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.98% | 35.89M | B- | ||
+7.15% | 220B | B | ||
+6.60% | 183B | B- | ||
+9.86% | 133B | B- | ||
+24.32% | 107B | A- | ||
-0.95% | 63.05B | A- | ||
+11.04% | 51.74B | B+ | ||
+4.81% | 50.47B | B+ | ||
-1.43% | 40.91B | A | ||
+24.40% | 31.91B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BOUL Stock
- Ratings Boule Diagnostics AB